In a move that highlights advancements in the healthcare sector in the UAE, the Emirates Drug Authority announced the approval of “Rilzabrutinib,” the first oral inhibitor of the protein tyrosine kinase enzyme for the treatment of immune thrombocytopenia. This action aligns with global efforts to provide advanced therapeutic solutions and reflects the UAE’s commitment to meeting patient needs by offering innovative treatments that adhere to international health standards.
Understanding Immune Thrombocytopenia
Immune thrombocytopenia is a rare disorder affecting approximately 2 to 5 individuals per 100,000 people worldwide. This condition is characterized by the body’s inability to produce platelets, exposing patients to various health risks. The approval of “Rilzabrutinib” is consistent with global trends aimed at ensuring effective solutions for treating this disorder.
Benefits of the New Treatment
The drug developed by Sanofi represents an innovative step in restoring immune system balance. “Rilzabrutinib” addresses the root causes of the disease by increasing platelet counts, significantly improving patients’ quality of life. Clinical trials have shown promising results, with many patients reporting noticeable improvements in their health conditions.
The Authority’s Commitment to Providing Advanced Treatments
Dr. Fatima Al Kaabi, Director General of the Emirates Drug Authority, emphasized that the approval of “Rilzabrutinib” enhances the country’s status as a leading hub for accelerating the availability of innovative treatments. She noted that this achievement is part of the Authority’s strategy to strengthen pharmaceutical security and adopt advanced therapeutic protocols, facilitating regulatory processes with international partners.
Collaboration Between Healthcare Institutions
Priti Fotenani, General Manager of Specialized Care at Sanofi for Saudi Arabia and the Gulf region, expressed her satisfaction with the fruitful collaboration with the Emirates Drug Authority. She highlighted the deep commitment to providing advanced therapeutic solutions that meet the needs of patients with immune thrombocytopenia, achieving shared goals of delivering high-quality healthcare.